DFCI Logo
DFCI Logo
Jia Luo, MD

Jia Luo, MD

Medical Oncology
MAKE AN APPOINTMENT

Contact Information

Office Phone Number

617-632-3468

Fax

617-632-5786

Appointments

617-632-3468

On This Page

Biography

Jia Luo, MD

Dr. Luo is a medical oncologist who specializes in care of people with lung cancer. Her approach to clinical care and research is informed by her unique background - learning laboratory research, programming, and clinical research skills during her training at institutions across the country. Dr. Luo strives to provide personalized compassionate care for patients and their families. Her research focuses on developing better treatments and treatment strategies by studying the genetic and immune characteristics of lung cancers. She also leads and develops clinical trials testing anticancer medicines that target cancers driven by these changes. Dr. Luo works with colleagues spanning the specialties involved in the care of people with lung cancer to develop the best treatment plans to increase the chance of cure. 

Researcher

Physician

Physician
Instructor in Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

Cell-free DNA, Immunotherapy, Lung cancer, Lung cancer biomarkers, Targeted therapies

Diseases Treated

Board Certification

  • Internal Medicine, 2017
  • Medical Oncology, 2022

Fellowship

  • Memorial Sloan Kettering Cancer Center, Medical Oncology

Residency

  • Oregon Health & Science University, Chief Resident in Internal Medicine
  • Oregon Health & Science University, Internal Medicine

Medical School

  • Stanford University School of Medicine

Recent Awards

  • Merit Award, American Society of Clinical Oncology (ASCO), 2021
  • Young Investigator Award (YIA), ASCO, 2020
  • Merit Award, ASCO, 2020
  • T32 Investigational Cancer Therapeutics Training Grant, 2019
  • Medical Oncology Grant, 2023
  • Lung Cancer SPORE Career Enhancement Program Grant, 2023

Research

    View Dr. Luo’s Research

    Dr Luo's research is focused on deciphering the genetic and immune characteristics of lung cancers to understand why some people benefit from anticancer medicines for a limited time while others have long term benefit lasting years. She aims to develop better tools to identify those who benefit from treatment and design clinical trials of new targeted therapies and immunotherapies to increase the chance of cure.

    She has first and co-authored papers in journals such as Cancer Discovery, Annals of Oncology, Nature Reviews Clinical Oncology, Cell Reports and Clinical Cancer Research. She has received grant support from foundations and the NIH.

    Research Departments

    Support my research

    Publications

      View Dr. Luo's Publications

      • Clinical approach and utilizing liquid biopsies to interrogate suspected acquired resistance to PD-1 blockade. Future Science OA. 2024. View in: Pubmed

      • Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024. View in: Pubmed

      • Diagnosis of NUT carcinoma of hepatic origin by next-generation sequencing. Frontiers in Oncology. 2024. View in: Pubmed

      • Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma. J Thorac Oncol. 2023 Dec 27. View in: Pubmed

      • Novel BRD2::NUTM1 fusion in NUT carcinoma with exceptional response to chemotherapy: A Case Report. JTO Clin Res Rep. 2023. View in: Pubmed

      • Journal for ImmunoTherapy of Cancer. Clinicopathologic, genomic and immunotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma. 2023. View in: Pubmed

      • Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):271-278. View in: Pubmed

      • The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma. Cancer Res. 2023 12 01; 83(23):3846-3860. View in: Pubmed

      • EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Res. 2023 12 01; 83(23):3956-3973. View in: Pubmed

      • Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 11 01; 29(21):4408-4418. View in: Pubmed

      • Proceedings Association for Molecular Pathology (AMP) Annual Meeting. Multiomic characterization and molecular profiling of NUT carcinoma. 2023. View in: Pubmed

      • Proceedings AACR-NCI-EORTC. A first-in-human study of CDK9 inhibitor KB-0742 demonstrates evidence of tolerability and clinical activity. 2023. View in: Pubmed

      • Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023 11; 18(11):1524-1537. View in: Pubmed

      • Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol. 2023 07; 34(7):589-604. View in: Pubmed

      • Thoracic Malignancies. Pocket oncology. Third edition / edited by Drilon, A. Vasan, N, Choudhury, N, Murciano-Goroff, YR. 2022. View in: Pubmed

      • Phase I trial of the TNF-a inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nat Commun. 2022 10 15; 13(1):6095. View in: Pubmed

      • Safety of image guided research biopsies in patients with thoracic malignancies. Lung Cancer. 2022 11; 173:53-57. View in: Pubmed

      • Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022 10; 3(10):1151-1164. View in: Pubmed

      • Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040. View in: Pubmed

      • Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol. 2022 08; 33(8):824-835. View in: Pubmed

      • High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep. 2022 Jun; 3(6):100328. View in: Pubmed

      • Overcoming KRAS-Mutant Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-11. View in: Pubmed

      • Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021 10; 16(10):1759-1764. View in: Pubmed

      • Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 09 15; 27(18):5131-5140. View in: Pubmed

      • Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer. Radiother Oncol. 2021 08; 161:115-117. View in: Pubmed

      • Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021 02; 9(2). View in: Pubmed

      • Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2021; 5. View in: Pubmed

      • Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. Cancer Discov. 2021 01; 11(1):59-67. View in: Pubmed

      • Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020 12; 10(12):1842-1853. View in: Pubmed

      • Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2). View in: Pubmed

      • COVID-19 in patients with lung cancer. Ann Oncol. 2020 10; 31(10):1386-1396. View in: Pubmed

      • MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020 09; 17(9):569-587. View in: Pubmed

      • Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 08; 10(8):1121-1128. View in: Pubmed

      • Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-12. View in: Pubmed

      • Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clin Cancer Res. 2020 06 15; 26(12):2849-2858. View in: Pubmed

      • A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. J Cancer Res Clin Oncol. 2019 Sep; 145(9):2303-2311. View in: Pubmed

      • Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists. Clin Breast Cancer. 2018 12; 18(6):498-503. View in: Pubmed

      • A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. Eur J Cancer. 2018 09; 101:143-151. View in: Pubmed

      • Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Res Rep Urol. 2016; 8:217-224. View in: Pubmed

      • Current Patterns of Care for Patients with Extensive-Stage SCLC: Survey of U.S. Radiation Oncologists on Their Recommendations Regarding Prophylactic Cranial Irradiation. J Thorac Oncol. 2016 08; 11(8):1305-1310. View in: Pubmed

      • AMP-Activated Protein Kinase Directly Phosphorylates and Destabilizes Hedgehog Pathway Transcription Factor GLI1 in Medulloblastoma. Cell Rep. 2015 Jul 28; 12(4):599-609. View in: Pubmed

      • Symptoms and palliative care needs of pancreatic adenocarcinoma patients. J Palliat Med. 2014 Jun; 17(6):640-1. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Jia Luo, MD

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights

      Back to Top